US OptionsDetailed Quotes
CYBN250117C17500
- 0.65
- 0.000.00%
15min DelayTrading Dec 3 11:45 ET
0.00High0.00Low
0.00Open0.65Pre Close0 Volume4 Open Interest17.50Strike Price0.00Turnover464.98%IV99.01%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier7DDays to Expiry0.65Extrinsic Value100Contract SizeAmericanOptions Type0.2473Delta0.0535Gamma14.03Leverage Ratio-0.1309Theta0.0003Rho3.47Eff Leverage0.0040Vega
Cybin Stock Discussion
Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results
Tuesday, 10th December at 7:30 am
- Poster presentations highlight clinical data across Cybin's CYB003 deuterated psilocin and DMT programs -
Cybin Inc. (NYSE: CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new...
PHOENIXVILLE, Pa., Dec. 4, 2024 /PRNewswire/ -- Facet Life Sciences, a leader in US regulatory strategy and product development solutions for the life sciences industry, has been named as the US regulatory partner for Cybin Inc. ("Cybin"), a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative treatment options to address the large unmet need for people ...
CCORF Maintains Cybin(CYBN.US) With Buy Rating, Maintains Target Price $86
trading under 12 now seems like something is in the works.
$Vertex Pharmaceuticals (VRTX.US)$ $Astera Labs (ALAB.US)$ $Emergent BioSolutions (EBS.US)$
$NVIDIA (NVDA.US)$ $Tesla (TSLA.US)$ $SoFi Technologies (SOFI.US)$
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
Cybin Inc. (NYSE American:CYBN)reported groundbreaking 12-month efficacy data from its Phase 2 study of CYB003 for major depressive disorder (MDD). After two 16mg doses administered three weeks apart, 100% of participants were responsive to treatment, with 71% in remission at 12 months. The study showed a ~23-point reduction in MADRS depression s...
No comment yet